Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1+PD-1 Monoclonal Antibody in Extensive-stage Small Cell Lung Cancer
NCT06437509Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of izalontamab brengitecan in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Primary endpoints: Objective Response Rate at 24 months and Recommended Phase II Dose at 24 months. Started Jun 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06437509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437509.